

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 6, 2020

James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 6 Butler Street, Camberwell VIC, 3124 Australia

> Re: Propanc Biopharma, Inc. Information Statement on Schedule 14C Filed June 11, 2020 File No. 000-54878

Dear Mr. Nathanielsz:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences